Literature DB >> 24012363

Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.

Ann Mullally1, Benjamin L Ebert.   

Abstract

The impact of myeloid malignancies on the nonhematopoietic components of the bone marrow remains poorly understood. In this issue of Cell Stem Cell, Schepers et al. (2013) describe how malignant myeloid cells alter the endosteal hematopoietic stem cell (HSC) niche, resulting in the expansion of osteoblastic lineage cells that preferentially support malignant HSCs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 24012363      PMCID： PMC3842099          DOI： 10.1016/j.stem.2013.08.009

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  9 in total

Review 1.  Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine.

Authors:  Paul S Frenette; Sandra Pinho; Daniel Lucas; Christoph Scheiermann
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.

Authors:  Koen Schepers; Eric M Pietras; Damien Reynaud; Johanna Flach; Mikhail Binnewies; Trit Garg; Amy J Wagers; Edward C Hsiao; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2013-07-11       Impact factor: 24.633

4.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

Authors:  Damien Reynaud; Eric Pietras; Keegan Barry-Holson; Alain Mir; Mikhail Binnewies; Marion Jeanne; Olga Sala-Torra; Jerald P Radich; Emmanuelle Passegué
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

5.  Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.

Authors:  Ingrid G Winkler; Natalie A Sims; Allison R Pettit; Valérie Barbier; Bianca Nowlan; Falak Helwani; Ingrid J Poulton; Nico van Rooijen; Kylie A Alexander; Liza J Raggatt; Jean-Pierre Lévesque
Journal:  Blood       Date:  2010-08-16       Impact factor: 22.113

6.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Authors:  Steffen Koschmieder; Berthold Göttgens; Pu Zhang; Junko Iwasaki-Arai; Koichi Akashi; Jeffery L Kutok; Tajhal Dayaram; Kristin Geary; Anthony R Green; Daniel G Tenen; Claudia S Huettner
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

Review 7.  Myeloproliferative neoplasm animal models.

Authors:  Ann Mullally; Steven W Lane; Kristina Brumme; Benjamin L Ebert
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

Review 8.  The hematopoietic stem cell niche.

Authors:  Dongsu Park; David B Sykes; David T Scadden
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche.

Authors:  Andrew Chow; Daniel Lucas; Andrés Hidalgo; Simón Méndez-Ferrer; Daigo Hashimoto; Christoph Scheiermann; Michela Battista; Marylene Leboeuf; Colette Prophete; Nico van Rooijen; Masato Tanaka; Miriam Merad; Paul S Frenette
Journal:  J Exp Med       Date:  2011-01-31       Impact factor: 14.307
  9 in total
  1 in total

Review 1.  Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors:  Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.